SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company developing immunotherapies and small-molecule drugs for hematologic and solid-tumor cancers. Its lead asset is galinpepimut-S (GPS), a WT1-targeted cancer vaccine licensed from Memorial Sloan Kettering Cancer Center, alongside tambiciclib (SLS009), a CDK9 inhibitor.
In Tuesday's session, the stock traded at $19.20 as of the afternoon, up $11.73, or 157.03%, from the prior session's close of $7.47. The direction was unmistakably upward. Shares opened at $24.11, reached a session high near $24.89, and cooled to a low around $16.70 before stabilizing — a violent open followed by heavy profit-taking. The immediate reason cited by markets was the positive Phase 3 REGAL readout, a genuinely binary event for the company.
The REGAL trial tested GPS as maintenance monotherapy in AML patients who had achieved a second or later complete remission after salvage therapy and who were ineligible for, or unable to undergo, a stem cell transplant — a population with few good options. The study met its primary endpoint of overall survival, with a statistically significant and clinically meaningful improvement over investigator-selected best available treatment.
Median overall survival of 24.0 months versus 14.7 months is a wide separation for a single-agent, off-the-shelf immunotherapy compared against physician-chosen combinations of hypomethylating agents, venetoclax, or low-dose cytarabine. The 41% reduction in risk of death, absent new safety concerns, is the kind of result that supports a registrational filing rather than a repeat study. For a company with no approved product and no revenue, that distinction is the entire investment case.
Management said it will meet the FDA to discuss an accelerated filing strategy and is preparing a Biologics License Application for GPS in the first half of 2027, alongside manufacturing and launch-readiness work. The company also framed the result as Phase 3 validation of its WT1-targeted technology, a protein overexpressed across roughly 20 tumor types, which broadens the perceived opportunity well beyond AML.
The secondary program, SLS009, adds optionality: preliminary topline data from an 80-patient Phase 2 trial in newly diagnosed AML are expected in the fourth quarter, and completed Phase 2 results in relapsed or refractory disease will be presented at the ASH annual meeting on December 12–15. Neither program was the reason for today's move, but both reinforce the narrative.
Volume was extraordinary: more than 109 million shares changed hands against a three-month average of roughly 6.5–6.9 million, an order of magnitude above normal turnover. The buying was not borrowed from the sector — biotech exchange-traded funds slipped between 0.5% and 0.6%, and small-cap benchmarks fell about 1.4% — so the divergence from the tape was near-total.
Technically, the gap left the stock far above every recent reference level. Shares had spent November grinding between roughly $7.50 and $9.00 after a months-long decline from August highs near $15.50, so the open near $24 cleared the entire prior range in a single print. The fade from the intraday high toward $19 reflects aggressive profit-taking into a market capitalization now near $3.9 billion, up from roughly $1.5 billion the day before.
The scale runs from 0, meaning no meaningful news and a move that is routine for the stock, to 100, meaning transformative news paired with an extreme and rare price move. The verified news here is about as strong as clinical-stage biotech news gets: a pivotal Phase 3 trial hitting its primary survival endpoint with a wide margin, unlocking a filing pathway. The price behavior was equally extreme, roughly 35 times the stock's typical absolute daily move of about 4.4%, and no session in the prior 60 came close to a move of this size. Those two components combine to 96 out of 100.
Attention turns to the FDA meeting and the timeline for a BLA submission, the disclosure of the complete dataset — including secondary endpoints, subgroup analyses, and immunologic correlates — at a major medical conference, and publication in a peer-reviewed journal. The ASH presentation in December and the SLS009 Phase 2 topline data expected this quarter are the next scheduled catalysts.
Analyst coverage remains thin, with a single Buy rating and a bullish long-term view that today's rally has already partly closed. Risks are substantial: regulatory timing can slip, the full dataset may reveal narrower benefit in subgroups, manufacturing scale-up for a biologic is capital-intensive, and a company with a $134.7 million cash position as of September 30 and a widening net loss may need to raise capital again. There is no guarantee of approval.
Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in the curated Trending AI Robots section. Bots differ widely by strategy, timeframe, performance metrics, and the symbols they trade, so the lineup shifts as market conditions change. Reviewing the current leaders is a practical way to see how automated strategies are adapting to today's volatility.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 53 similar instances where the stock broke above the upper band. In 47 of the 53 cases the stock fell afterwards. This puts the odds of success at 89%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals
Industry Biotechnology